Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elbasvir/grazoprevir - Merck and Co

Drug Profile

Elbasvir/grazoprevir - Merck and Co

Alternative Names: Elbasvir and grazoprevir; Grazoprevir/elbasvir; MK-5172/MK-8742; MK-5172A; MK-8742/MK-5172; ZEPATIER

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Amides; Antivirals; Benzoxazines; Carbamates; Carboxylic acids; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Nov 2020 Updated pharmacokinetics and adverse events data from MK-5172-079 phase II trial in hepatitis C virus presented at the 70th Annual Meeting of the American Association for the Study of Liver Disease (AASLD-2020)
  • 23 Jul 2020 Merck Sharp & Dohme completes a phase II trial in Hepatitis C (In children, In adolescents) in Sweden, Poland, Germany, USA (PO) (EudraCT2015-003006-16) (NCT03379506)
  • 30 Nov 2019 University of Pennsylvania and Merck completes a phase I/II trial for Hepatitis C in USA (NCT03146741)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top